Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Delayed Nasdaq Copenhagen 11:59:47 2024-03-27 am EDT 5-day change 1st Jan Change
881.3 DKK -0.79% Intraday chart for Novo Nordisk A/S -2.29% +26.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk Asked by Bernie Sanders to Lower List Price of Diabetes, Weight-Loss Drug MT
Novo Nordisk, Eli Lilly, Sanofi Control More Than 90% of Global Insulin Market, JAMA Study Shows MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Amazon Pharmacy Reaping Benefits of Demand for Anti-Obesity Drugs, Executive Says MT
How to learn from your mistakes with François Rochon Our Logo
NOVO NORDISK : UBS sticks Neutral ZD
Eli Lilly's Zepbound Set to Be Key 2024 Revenue Maker as Weight-Loss Drug Usage Surges MT
Health Care Down on Deal Skepticism -- Health Care Roundup DJ
Deals of the day-Mergers and acquisitions RE
European Equities Close Flat in Monday Trading; European Commission Opens Competition Probes Into Apple, Google, Meta MT
News Highlights : Top Company News of the Day - Monday at 11 AM ET DJ
Dpa-AFX Overview: COMPANIES from 25.03.2024 - 15:15 DP
News Highlights : Top Company News of the Day - Monday at 9 AM ET DJ
Novo ready to seek German insurance coverage of Wegovy for heart use RE
Novo Nordisk to Acquire Cardior Pharmaceuticals for up to $1.11 Billion MT
News Highlights : Top Company News of the Day - Monday at 7 AM ET DJ
NOVO NORDISK : Barclays maintains a Buy rating ZD
Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to $1.11 Billion MT
Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals -- Update DJ
Novo Nordisk to Buy Cardior Pharmaceuticals in EUR1 Billion Deal MT
Novo Nordisk Boosts Cardiovascular Pipeline With EUR1 Billion Cardior Pharmaceuticals Buy DJ
Novo Nordisk: acquisition of Cardior Pharmaceuticals CF
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes treatment products (78.9%); - rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.; - obesity treatment products (9.5%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
881.3 DKK
Average target price
909.4 DKK
Spread / Average Target
+3.19%
Consensus
  1. Stock
  2. Equities
  3. Stock Novo Nordisk A/S - Nasdaq Copenhagen
  4. News Novo Nordisk A/S
  5. Novo Nordisk to Invest More Than $2.68 Billion to Expand Manufacturing Capability in Kalundborg, Denmark